康恩贝：子公司TFA003片药物临床试验获批

Core Viewpoint - Kangnbei (600572.SH) has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, aimed at treating diabetic nephropathy, indicating a significant step in addressing a market gap for effective treatments in this area [2] Company Summary - Kangnbei's wholly-owned subsidiary, Hangzhou Kangnbei Pharmaceutical Co., Ltd., has been granted a Clinical Trial Approval Notice for TFA003 tablets, which are classified as Traditional Chinese Medicine (TCM) under categories 2.1 and 2.3 [2] - The company has invested approximately 29.57 million yuan in the research and development of TFA003 [2] Industry Summary - There is a limited number of drugs available in both domestic and international markets for the treatment of diabetic nephropathy, with current clinical treatments primarily consisting of hypoglycemic and antihypertensive medications [2] - No other TCM products with significant efficacy for the same indication have been launched in the market, highlighting a unique opportunity for Kangnbei with TFA003 [2]